SCHEMBL22904148

SCHEMBL22904148

O=C1Cc2cccc(Oc3ccccn3)c2C(=O)N1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP2 O95551 10/20 0.48
KDM4E B2RXH2 1/20 0.43
CASP3 P42574 1/20 0.42
CASP7 P55210 1/20 0.42
CASP9 P55211 1/20 0.42
CASP6 P55212 1/20 0.42
CASP8 Q14790 1/20 0.42
MAP3K14 Q99558 1/20 0.42
FFAR4 Q5NUL3 3/20 0.37
AHR P35869 2/20 0.37
PDK2 Q15119 1/20 0.37
KCNH2 Q12809 1/20 0.35
CHEK1 O14757 1/20 0.33
AURKA O14965 1/20 0.33
DAPK3 O43293 1/20 0.33
PRKD3 O94806 1/20 0.33
MAP4K4 O95819 1/20 0.33
ABL1 P00519 1/20 0.33
NTRK1 P04629 1/20 0.33
CSF1R P07333 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11089552 0.84 KDM4E (0.46) TDP2KDM4ECASP3CASP7CASP9
SCHEMBL22904525 0.79 TDP2 (0.54) TDP2CASP3CASP7CASP9CASP6
SCHEMBL9519108 0.78 KDM4E (0.48) KDM4ECASP3CASP7CASP6CASP8
SCHEMBL22904393 0.77 TDP2 (0.51) TDP2CASP3CASP7CASP9CASP6
SCHEMBL22904129 0.77 AHR (0.54) TDP2CASP3CASP7CASP9CASP6
SCHEMBL22904128 0.77 TDP2 (0.51) TDP2CASP3CASP7CASP9CASP6
SCHEMBL22904252 0.77 TDP2 (0.51) TDP2KDM4ECASP3CASP7CASP9
SCHEMBL22904103 0.77 TDP2 (0.51) TDP2CASP3CASP7CASP9CASP6
SCHEMBL22904285 0.76 TDP2 (0.50) TDP2KDM4ECASP3CASP7CASP9
SCHEMBL22904369 0.75 TDP2 (0.50) TDP2CASP3CASP7CASP9CASP6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021011631-A1 FUSED-GLUTARIMIDE CRBN LIGANDS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-01-21 WO disclosed